Selective JAK1/2 pathway inhibition has resulted in significant improvements for AD patients (Kim et al., 2020; Tsai et al., 2021) and even in dogs, the JAK1/2 inhibitor oclacitinib is used for treating AD (Cosgrove et al., 2013). This evidence concerns the gene JAK1 and Alzheimer disease.